Quarterly ResultMay 20, 2026, 04:23 PM
20/20 BioLabs Q1 Revenue $0.4M, Net Loss $2.2M; Cash $4.2M
AI Summary
20/20 BioLabs reported Q1 2026 financial results with revenue of $0.4 million, a decrease from $0.6 million in Q1 2025, and a net loss of $2.2 million, up from $0.8 million in the prior year. Despite the decline in Q1 revenue due to timing of orders, the company significantly strengthened its cash position to $4.2 million as of March 31, 2026, following a $5.0 million private placement. Operational highlights include expected meaningful revenue growth from state-funded firefighter cancer screening programs starting in Q2 2026, the launch of OneTest for Longevity, and a distribution agreement with Evexia Diagnostics.
Key Highlights
- Q1 2026 revenue was $0.4 million, down from $0.6 million in Q1 2025.
- Q1 2026 net loss was $2.2 million, compared to $0.8 million in Q1 2025.
- Cash and cash equivalents totaled $4.2 million as of March 31, 2026, up from $1.0 million.
- Completed a $5.0 million private placement, strengthening the cash position.
- Deferred revenue increased to $0.5 million as of March 31, 2026.
- Expected Q2 revenue growth from state-funded firefighter cancer screening programs.
- Launched OneTest for Longevity and partnered with Evexia Diagnostics.
- Commenced trading on Nasdaq Capital Market under AIDX on February 19, 2026.
Price Impact
More from AIDX